neuroClues closes €10M Series A to bring its eye-tracking Parkinson’s diagnostic to European and US neurologists

📰 The Next Web AI

neuroClues raises €10M Series A to expand its eye-tracking diagnostic for neurodegenerative diseases

intermediate Published 7 Apr 2026

Action Steps

Utilize portable headsets to capture infrared images of patients' eyes
Extract oculomotor biomarkers from the images to indicate neurodegenerative diseases
Analyze the biomarkers to predict the onset of diseases like Parkinson's, Alzheimer's, and multiple sclerosis
Integrate the technology with existing healthcare systems to improve diagnosis and treatment

Who Needs to Know This

Medical professionals, neurologists, and researchers can benefit from this technology to improve diagnosis and treatment of Parkinson's, Alzheimer's, and multiple sclerosis. The development team, including AI engineers and data scientists, can leverage this technology to improve healthcare outcomes

Key Insight

💡 Eye-tracking technology can detect neurodegenerative diseases years before clinical symptoms appear